Breaking Research News from sources other than Breastcancer.org
Comments
-
"Hypofractionated Breast Radiotherapy for 1 Week Noninferior to 3 Weeks"
Wow, this will make a big difference in the experience of treatment for many people, and I think make compliance much more feasible for women with less flexible work options.
0 -
Salamandra: I agree. I had to read it twice (or more) to be sure I understood it correctly. Many women have foregone lumpectomy owing to the burdens of the follow up radiation schedule. Travel and transporation to care, time off work and numerous other complications can be issues. A dramatically shortened schedule would make this less invasive surgery a more feasible option for some.
0 -
Carbohydrate quality index and breast cancer risk in a mediterranean cohort: The SUN project
(Summary of Clinical Nutrition — Romanos-Nanclares A, Gea A, Martínez-González MA, et al. | May 11, 2020, https://www.mdlinx.com/ct.cfm?cid=7686001&typ=js&rdr=https://www.clinicalnutritionjournal.com/article/S0261-5614(20)30211-9/fulltext?rss=yes&mor=1)
In this study, the relationship between an a priori defined carbohydrate quality index (CQI) and the incidence of BC were tested in a Mediterranean cohort study. A validated semi-quantitative 136-item food-frequency questionnaire was applied in a prospective follow-up study of 10,812 middle-aged women. Researchers assessed the CQI following 4 criteria at baseline: dietary fiber intake, glycemic index, whole grain:total grain ratio and the solid carbohydrate:total carbohydrate ratio. Subjects were classified into quartiles according to the final CQI score. This Mediterranean cohort exhibited a significant inverse association with the incidence of BC after a better quality of dietary carbohydrate intake, which imply that strategies for cancer prevention should demonstrate the quality of this macronutrient.
https://www.mdlinx.com/journal-summaries/breast-cancer-nutrition/2020/05/11/7686001/
0 -
Caution on prolonged wearing of masks for those with cancer:
People with cancer, especially if the cancer has spread, will be at a further risk from prolonged hypoxia as the cancer grows best in a microenvironment that is low in oxygen. Low oxygen also promotes inflammation which can promote the growth, invasion and spread of cancers.8,9 Repeated episodes of hypoxia has been proposed as a significant factor in atherosclerosis and hence increases all cardiovascular (heart attacks) and cerebrovascular (strokes) diseases.
https://www.technocracy.news/blaylock-face-masks-pose-serious-risks-to-the-healthy/
0 -
That website- technocracy.news is not an credible news site and the article doesn't contain accurate scientific information.
0 -
The writing has some real slips of logic.
0 -
Hi All, We are wondering how many of you read our research news articles. We're thinking of getting a group together to get some feedback. Would you PM us Mods to let us know if you do? Thank you!
0 -
would be good if you put it in a thread so we could mark it under favourites
0 -
Kanga - there is a thread. Here's the link. Interestingly I mostly read the articles, either here or there, that are relevant to my diagnosis & treatment.
https://community.breastcancer.org/forum/73/topics...
0 -
New Map Reveals Distrust in Health Expertise Is Winning Hearts and Minds Online
Researchers warn scientists are fighting health misinformation in the wrong place.
Communities on Facebook that distrust establishment health guidance are more effective than government health agencies and other reliable health groups at reaching and engaging "undecided" individuals, according to a first-of-its-kind study published today by researchers at George Washington University and other institutions in the journal Nature.
The researchers tracked the vaccine conversation among 100 million Facebook users during the height of the 2019 measles outbreak. The new study and its "battleground" map reveal how distrust in establishment health guidance could spread and dominate online conversations over the next decade, potentially jeopardizing public health efforts to protect populations from COVID-19 and future pandemics through vaccinations.
https://www.nature.com/articles/s41586-020-2281-1
Johnson, N.F., Velásquez, N., Restrepo, N.J. et al. The online competition between pro- and anti-vaccination views. Nature (2020). https://doi.org/10.1038/s41586-020-2281-1
0 -
Impact of Stopping Trastuzumab in Early Breast Cancer
- Journal of the National Cancer Institute This retrospective study was designed to evaluate the impact of early discontinuation of adjuvant trastuzumab on outcomes in patients with early-stage HER2+ breast cancer. Early discontinuation of trastuzumab was associated with an increased risk of relapse and death.Adjuvant trastuzumab should be continued for a year in patients with early-stage breast cancer.CONCLUSIONS: BC patients in Ontario who did not complete adjuvant trastuzumab had a statistically significantly higher risk of BC relapse and death and low incidence of cardiac death. These findings support one year of adjuvant trastuzumab in early stage BC.https://www.practiceupdate.com/C/100061/56?elsca1=emc_enews_topic-alerthttps://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djaa054/5826355?redirectedFrom=fulltexthttps://doi.org/10.1093/jnci/djaa054
0 -
A sincere and very interesting article: https://www.onclive.com/publications/Oncology-live/2020/vol-21-no-10/looking-forward-to-a-new-wave-of-breast-cancer-therapies
0 -
BSandra, thanks for sharing that very interesting article. My MO informed me that I am now HER2-low, so that trial especially piqued my interest.
0 -
Dear Bliss, dear ShetlandPonny, I htink you could well chat together about Her2low. ShetlandPonny just got a PhD in Her2low/Her2mut:>, and could really help with explaining how to use this situation to make you benefit. Might be you are eligible for the same clinical trial, if they still recruit? Saulius
0 -
'They killed her': Why are breast implants still putting millions of women at risk?
Allergan's "medical aesthetics" products helped persuade AbbVie to buy the company. But what if the devices driving profit are also endangering women's health?
Press coverage of breast implant issue: "The causes of the various problems with breast implants are still poorly understood, which public health experts blame on a lack of testing or objective, long-term studies that do not rely on manufacturer-provided data or funding. Device makers also have yet to fully report the data the FDA required as a condition of allowing silicone implants back on the market in 2006."
https://fortune.com/longform/breast-implants-dangerous-allergan-abbvie-acquisition/?j16sc8
0 -
I'm also low her2. Her2- by fish. I've been reading articles about how they are starting clinical trials for us using some of the her2 drugs. It's very promising as I know there are quite a few her2 women out there that have done well. Shetland, are you low her2 or did yours mutant to her2?
0 -
An arm of the DS8201a/Enhertu trial was taking low HER2 patients.
0 -
Thanks Lumpie. I'll pull up the trial and take a look at it.i've been on I\L for a year and a half and have been doing well. I also know that the combo has an avg of 27 months, so I know it's just a matter of time before my cancer wakes up again. I am interested trying a clinical trial so I'll check it out.
0 -
Here's a link:
ClinicalTrials.gov Identifier: NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
https://clinicaltrials.gov/ct2/show/NCT03734029?term=DS-8201a&cond=Breast+Cancer&draw=2&rank=4BTW, It's for unresectable, and/or metastatic breast cancer.
PS: Simone80: Hope you don't need to change Tx for a long time. I was on a different branch of the Destiny trial. It was a great experience. The clinical trial staff and medical director at my site were fabulous. Good luck!
0 -
Interesting information as always. Lumpie thanks for the article on the PALVEN trial, that’s a hopeful one for those of us on I/L
0 -
Thanks Lumpie. I hope to get another year out of I\L, but just in case.
0 -
Simone, to answer your question, the cancer acquired a mutation in the HER2/ERBB2 gene. It is still HER2 negative (non-amplified).
0 -
Wallygal posted this in Clinical trails/research. I am reposting it here. Interesting report on Genome Study (no the original study) in ScienceDaily, more DNA variations found that might be linked to BC. https://www.sciencedaily.com/releases/2020/05/200518144849.htm . Has anyone else had a genetic profile done that insurance denied ? My DR ordered one Sept 2019 when 3rd BC found, specific to BC, looking at at over 20 markers (none found). Insurance sent me an official denial, the lab who did the work is fighting it,
0 -
BlueGirl: denied after your 3rd BC? That is outrageous! It's standard of care! How can insurance get away with that? I hope that you will let your legislators, both state and federal, know about this. How insurers can get away with not covering standard of care is beyond me! It should not happen.
0 -
Shetland, MO said the pathologist told her she labeled me HER2 negative because there were fewer than 10% cells; the report says 8%. Does that mean non-amplified? MO is keeping me on current tx for now.
0 -
Reading all the posts in various forums, it is increadible what is covered/what it not, the care, advice etc people get. The denial is being appealed, and one patient support advocate felt confident that insurance would cover all or most of it. Contacting my representatives is a waste of time. I have contacted them on several issues including health, and their replies often do not address what I wrote about, or are non-commital, or tell me why I am wrong. We passed an initiative on the ballot to expand Medicaid in this state, and legislators made an attempt to weaken or get rid of it (they failed). They also made an attempt to make the initiative process much more difficult. ( We know more than you do). So far that has failed as well. I do not celebrate the idea of "Medicare for All", because the focus is on insurance/who pays/how much, and not on health care itself. I know some people have no or poor coverage and this would be a chance to pay for treatment they cannot afford. So Medicare is certianly is part of the equation. The other day there was an interview on NPR with a woman whose surgery for BC had been postponed because of covid-19. Her tumor has grown a lot, and the treatment she now requires, is much more invasive. It sounded less hopeful as well.
0 -
Dear all, these are not breaking news but we have to keep an eye on Tesetaxel, an oral Taxane. It achieved high response rates in clinical trials even in patients pretreated with other taxanes. I know ow amazing Docetaxel was for my wife, and Tesetaxel (not to mention it is oral) seems very promising:
https://www.ascopost.com/issues/july-25-2018/oral-...
https://www.odonate.com/tesetaxel.
Saulius
0 -
Saulius, thanks so much for the article. I was not aware of Tesetaxel. I will investigate further with my own MO. Very encouraging!
0 -
DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
May 23, 2020
Publication: Cells (Open access)
Trastuzumab emtansine (T-DM1) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugated to the microtubule-targeting agent emtansine (DM1). T-DM1 is an effective agent in the treatment of patients with HER2-positive breast cancer whose disease has progressed on the first-line trastuzumab containing chemotherapy. However, both primary and acquired tumour resistance limit its efficacy. Increased levels of the phosphorylated form of Translationally Controlled Tumour Protein (phospho-TCTP) have been shown to be associated with a poor clinical response to trastuzumab therapy in HER2-positive breast cancer. Here we show that phospho-TCTP is essential for correct mitosis in human mammary epithelial cells. Reduction of phospho-TCTP levels by dihydroartemisinin (DHA) causes mitotic aberration and increases microtubule density in the trastuzumab-resistant breast cancer cells HCC1954 and HCC1569. Combinatorial studies show that T-DM1 when combined with DHA is more effective in killing breast cells compared to the effect induced by any single agent. In an orthotopic breast cancer xenograft model (HCC1954), the growth of the tumour cells resumes after having achieved a complete response to T-DM1 treatment. Conversely, DHA and T-DM1 treatment induces a severe and irreversible cytotoxic effect, even after treatment interruption, thus, improving the long-term efficacy of T-DM1. These results suggest that DHA increases the effect of T-DM1 as poison for microtubules and supports the clinical development of the combination of DHA and T-DM1 for the treatment of aggressive HER2-overexpressing breast cancer.
0 -
PD-L1 And What It Means In Cancer Treatement
https://www.whatnext.com/blog/posts/pd-l1-and-what-it-means-in-cancer-treatement
{Not research, per se, but an brief and accessible article about PD-L1, a bit of history of immunotherapy research, and a very brief explanation of how immunotherapy attempts to work.}
0
